Business
Research Reports Initiated on Healthcare Stocks Cardiome Pharma, ProMetic Life Sciences, Cronos Group, and biOasis Technologies
LONDON, UK / ACCESSWIRE / March 16, 2017 / Active Wall St. announces the list of stocks for ...
About this update from Cronos Group Inc
[{"type":"text","content":"Research Reports Initiated on Healthcare Stocks Cardiome Pharma, ProMetic Life Sciences, Cronos Group, and biOasis TechnologiesLONDON, UK / ACCESSWIRE / March 16, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Cardiome Pharma, ProMetic Life Sciences, Cronos Group, and biOasis Technologies. Get all of our free research reports by signing up at:\n \nhttp://www.activewallst.com/register/ \n \nOn Wednesday, March 15, 2017, at the end of trading session, the Toronto Exchange Composite index ended the day at 15,520.91, 0.92% higher, with a total volume of 430,060,332 shares. The TSX Venture Composite Index, on the other hand, closed at 807.28, up 1.82%.\n \nAdditionally, the Healthcare index was slightly up by 0.31%, ending the session at 68.62. \n \nActive Wall St. has initiated research reports on the following equities: Cardiome Pharma Corporation (TSX: COM), ProMetic Life Sciences Inc. (TSX: PLI), Cronos Group (TSX-V: MJN), and biOasis Technologies Inc. (TSX-V: BTI). Register with us now for your free membership and research reports at:\nhttp://www.activewallst.com/register/\nCardiome Pharma Corp.\n \nOn Wednesday, shares in Vancouver, Canada-based Cardiome Pharma Corp. recorded a trading volume of 16,864 shares, which was higher than their three months average volume of 9,035 shares. The stock ended the day flat at $4.10. Cardiome Pharma Corp.'s stock has gained 5.13% in the last one month and 15.49% in the previous three months. Shares of the Company, which engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients suffering from heart diseases, are trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $3.92 is above its 200-day moving average of $3.87. See our research report on COM.TO at:\n \nhttp://www.activewallst.com/register/\nProMetic Life Sciences Inc.\n \nOn Wednesday, shares in Laval, Canada headquartered ProMetic Life Sciences Inc. ended the session flat at $2.39 with a total volume of 599,845 shares traded. ProMetic Life Sciences' shares have gained 21.32% in the past three ...